Search the Newsreel

Oppenheimer Asset Management Inc. Sells 127,394 Shares of BCE, Inc. $BCE

Oppenheimer Asset Management Inc. reduced its stake in BCE, Inc. by 20.8% in the second quarter, selling 127,394 shares and retaining 485,021 shares valued at $10.4 million. Despite this, other major institutional investors like FIL Ltd, Caisse de dépôt et placement du Quebec, and …

Fox Run Management L.L.C. Sells 46,340 Shares of BCE, Inc. $BCE

Fox Run Management L.L.C. significantly reduced its stake in BCE, Inc. by selling 46,340 shares, leaving them with 12,212 shares valued at $263,000. Despite this, institutional investors collectively own 41.46% of BCE, and analysts maintain a "Moderate Buy" rating with an average price target …

Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will …

BCE Inc. stock rises Friday, outperforms market

BCE Inc. (BCE) shares increased by 0.34% to C$32.57 on Friday, outperforming the broader Canadian market which saw the S&P/TSX Composite Index (GSPTSE) fall by 0.08%. The stock's performance occurred during a generally poor trading session for the Canadian market. BCE Inc. closed 10.2% …

AbCellera Biologics Stock 6-Day Winning Spree: Stock Climbs 85%

6 Green Days In A Row: AbCellera Biologics Stock Is Up 85%

AbCellera Biologics (ABCL) stock has surged 85% over six consecutive trading days, reaching a new 52-week high and adding $1.5 billion to its market value. While its revenue growth is strong at 101.3% over the last twelve months, the company faces profitability challenges with …

BCE (BCE) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Mirko BibicChief Financial Officer - Curtis MillenKrishna Somers TAKEAWAYS Consolidated Revenue -- increased 1.5% year over year, driven by the contribution from …

AbCellera Biologics Inc. • Robinhood Token (ABCL) Price Prediction for 2026 to 2031

This article provides price predictions for AbCellera Biologics Inc. • Robinhood Token (ABCL) from 2026 to 2045, based on Bybit AI's analysis of user-driven Consensus Ratings and historical patterns. It forecasts a positive trend for ABCL's price, with significant potential ROI over the years, …

BCE Inc. stock rises Thursday, outperforms market

BCE Inc. (BCE) stock increased by 0.71% to C$32.46 on Thursday, outperforming the broader Canadian market as the S&P/TSX Composite Index rose by 0.26%. The company's shares closed 10.5% below their 52-week high of C$36.25, which was set on March 17th.

BCE Inc. Stock Under Pressure: Weak Sentiment, Telecom Headwinds and Rising Downside Risk

AbCellera Biologics prices oversubscribed $200M offering at $9.75/share

AbCellera Biologics (ABCL [https://seekingalpha.com/symbol/ABCL]) announced the pricing of its oversubscribed underwritten public offering [https://seekingalpha.com/pr/20617674-abcellera-announces-pricing-of-oversubscribed-200-million-public-offering-of-common-shares] of 17.44M common shares at $9.75 per share. In lieu of common shares, AbCellera is also offering pre-funded warrants to purchase up to 3.08M common shares at $9.74999 per warrant …

AbCellera (ABCL) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 5:00 p.m. ET CALL PARTICIPANTS Chief Legal and Compliance Officer - Tryn Stimart President and Chief Executive Officer - Carl L. Hansen Chief Financial Officer - Andrew Booth Full Conference Call Transcript Operator: …

AbCellera Biologics (NASDAQ:ABCL) Shares Gap Down - Here's Why

BCE Inc. stock falls Wednesday, underperforms market

BCE Inc. stock declined by 0.77% to C$32.23 on Wednesday, underperforming the broader Canadian market as the S&P/TSX Composite Index rose by 0.51%. The company's shares closed 11.1% below their 52-week high reached in March.

BCE Stock Climbs 10.2% in One Month. Can the Rally Sustain Its Pace?

BCE Inc. shares have rallied 10.2% in the past month, fueled by higher revenues and adjusted earnings in Q2. However, significant capital expenditures, increased leverage, and declining earnings estimates suggest that the recent pace of the rally may not be sustainable. While fiber, media, …

AbCellera Biologics Inc. (NASDAQ:ABCL) Given Consensus Recommendation of "Moderate Buy" by Analysts

AbCellera Biologics Inc. (NASDAQ:ABCL) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $12.83, notably boosted by Truist Financial's increased target of $30. The company's shares have rallied significantly following positive Phase 2 results for its experimental …

Is BCE Stock Worth Buying as Low Valuation Meets Execution Risks?

BCE Inc. presents a value-versus-execution trade-off, with shares screening cheaply but facing an earnings reset, high leverage, and capital-intensive expansion into AI and U.S. fiber. While its low valuation is a positive, the company needs operational progress to improve earnings and cash-flow visibility. The …

Revenue Downgrade: Here's What Analysts Forecast For AbCellera Biologics Inc. (NASDAQ:ABCL)

Analysts have recently downgraded their revenue forecasts for AbCellera Biologics Inc. for 2024 and 2025, suggesting a more cautious outlook on the company's near-term growth prospects. Despite the revised estimates, the average price target for ABCL stock remains unchanged, implying that analysts see potential …

BCE INC. : BOFA GLOBAL RESEARCH RAISES TO BUY FROM UNDERPERFORM RATING

BofA Global Research has upgraded its rating for BCE Inc. (BCE.TO) from "underperform" to "buy." This change in recommendation suggests a more positive outlook on the company's stock by the research firm. The article, sourced from Reuters, was published by Bitget News.

ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL)

AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz Deal

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. The latest analyst update on AbCellera Biologics reflects a higher Fair Value estimate of …

AbCellera Biologics (ABCL) On ABCL635 Trial Results And A Richer Valuation Story

AbCellera stock falls on $200M public offering launch

AbCellera Biologics Inc. (NASDAQ:ABCL) shares dropped 3.7% after the company announced a $200 million underwritten public offering of common stock and pre-funded warrants. The biotechnology company intends to use the net proceeds to fund research, development, and clinical advancement of its internal pipeline, including …

Truist Financial Issues Positive Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price

AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 8.7% - Here's What Happened

BCE Upgraded by B of A Securities -- Price Target Raised to $27.

BCE (BCE) has been upgraded by B of A Securities from "Underperform" to "Buy," with its price target raised to $27.00 from $24.50, reflecting a positive sentiment shift. GuruFocus indicates BCE is undervalued by 11.4% with a GF Value™ of $25.44, and its GF …

BCE, Inc. (NYSE:BCE) Receives Consensus Rating of "Hold" from Analysts

BCE, Inc. (NYSE:BCE) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $30.00. The company recently reported quarterly earnings of $0.47 per share, beating estimates, and revenue of $4.35 billion, matching expectations. BCE also declared a quarterly dividend …

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

AbCellera (Nasdaq: ABCL) is set to release top-line data from its Phase 2 trial of ABCL635 for moderate-to-severe vasomotor symptoms (VMS) due to menopause on Monday, August 10, 2026. The company will also host an investor conference call and webcast to discuss the results. …

AbCellera (ABCL) Rockets 44% as Hot Flash Treatment Brightens Growth Outlook

AbCellera Biologics (ABCL) surged 44% to a three-year high following positive clinical trial results for its hot flash treatment, ABCL635. The drug significantly reduced hot flashes in postmenopausal women, outperforming a placebo, and analysts are bullish on its potential in a large addressable market. …

AbCellera stock soars on ‘off the chart’ trial results from hot flash treatment for menopausal women

AbCellera Biologics Inc. saw its stock soar after announcing "off the chart" human trial results for its hot flash treatment, ABCL635, which proved more effective and had fewer side effects than existing therapies. The drug, aimed at menopausal women and those undergoing hormone-suppressing cancer …

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

AbCellera has announced positive top-line results from its Phase 2 clinical trial for ABCL635, an investigational antibody for treating moderate-to-severe vasomotor symptoms (hot flashes) in menopausal women. The study demonstrated statistically significant reductions in both the frequency and severity of symptoms, as well as …

AbCellera Biologics Sees Unusually High Options Volume (NASDAQ:ABCL)

AbCellera Biologics (NASDAQ:ABCL) experienced unusually high options trading volume, with investors purchasing 16,666 call options, a 151% increase over the average. The company's shares surged by $2.37 to $9.30 on heavy trading volume, despite missing analyst expectations for both earnings and revenue in its …

Abcellera Biologics stock hits 52-week high at 8.79 USD

Abcellera Biologics Inc. (ABCL) reached a 52-week high of $8.79, reflecting a 63% total return over the past year and 119% over six months. Despite this, an InvestingPro analysis suggests the stock may be overvalued. The company also announced positive Phase 2 clinical trial …